On the 20th, 18.53 million tokens will be unlocked from specific addresses related to Kaito (KAITO), with an additional 6.58 million tokens being released sequentially on September 16-17. Crypto Painter has advised investors to remain cautious until at least October. Masbit cited Crypto Painter's analysis, reporting that a large volume of tokens will be released from the specified address. Analysts criticized Kaito for shipping out tokens after recently announcing positive news, considering it market manipulation. CoinGecko stated that on the 20th, 32.6 million tokens, or 3.3% of Kaito's total supply (1 billion), are expected to be released. Crypto Painter simplified Kaito's observation criteria to whether the new product ecosystem is actually taking root, explaining that if it recovers to the level of social buzz and scale seen in 2025, Kaito could position itself as a leader in the 'InfoFi' sector. Conversely, they added that if product supply does not meet expectations, they would not consider restaking. He diagnosed that most of the large unlock volume has already been hedged and liquidated, meaning that the spot supply has not been fully released. The real signal for supply release is when the spot price significantly lags behind the futures price, maintaining a high funding rate, accompanied by a price drop in trading volume. Kaito has previously revealed plans to distribute unallocated tokens to active stakers through a revision of its staking reward mechanism.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.











Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.